Publications by authors named "P S Yamauchi"
Background: In the primary analysis of a Phase 3b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe plaque psoriasis affecting the scalp (NCT03897088), tildrakizumab, an anti-interleukin-23 p19 antibody, met the primary efficacy endpoint at Week (W)16.
Objective: To evaluate maintenance of tildrakizumab efficacy and safety for the treatment of scalp psoriasis from the W52 full analysis.
Methods: Patients randomized to tildrakizumab continued receiving tildrakizumab 100 mg every 12 weeks; patients randomized to placebo (analyzed separately) switched to tildrakizumab 100 mg at W16.
Article Synopsis
- ABP 654 is a biosimilar to ustekinumab, sharing identical amino acid sequences and similar safety and pharmacokinetics in healthy individuals.
- A clinical study was conducted to compare the efficacy and safety of ABP 654 versus ustekinumab in patients with moderate-to-severe plaque psoriasis, focusing on improvements in psoriasis severity.
- Results showed no significant difference in efficacy (PASI improvement) between ABP 654 and ustekinumab, and both treatments exhibited similar safety and immunogenicity profiles.
Background: Scalp psoriasis is common and difficult to treat.
Objective: To evaluate efficacy and safety of tildrakizumab for the treatment of scalp psoriasis.
Methods: In this Phase 3b, randomized, double-blind, placebo (PBO)-controlled study (NCT03897088), patients with moderate-to-severe plaque psoriasis affecting the scalp (Investigator Global Assessment modified [IGA mod] 2011 [scalp] ≥3, Psoriasis Scalp Severity Index [PSSI] ≥12, ≥30% scalp surface area affected) received tildrakizumab 100 mg or PBO at W0 and W4.